NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Trading Down 8.4%

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY)’s stock price was down 8.4% during mid-day trading on Monday . The company traded as low as $0.90 and last traded at $0.87, approximately 6,532 shares were traded during trading. A decline of 99% from the average daily volume of 1,226,033 shares. The stock had previously closed at $0.95.

NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) last issued its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.12) by ($0.12). The firm had revenue of $1.49 million during the quarter.

In other news, major shareholder Pharma (Hong Kong) Co Pioneer sold 24,326 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $4.04, for a total transaction of $98,277.04. Following the completion of the sale, the insider now owns 5,188,421 shares in the company, valued at approximately $20,961,220.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Mijia Wu sold 63,492 shares of the business’s stock in a transaction dated Tuesday, June 11th. The stock was sold at an average price of $2.53, for a total value of $160,634.76. The disclosure for this sale can be found here.

An institutional investor recently raised its position in NovaBay Pharmaceuticals stock. Renaissance Technologies LLC boosted its stake in NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) by 1,283.0% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 412,469 shares of the biopharmaceutical company’s stock after acquiring an additional 382,645 shares during the quarter. Renaissance Technologies LLC owned about 1.96% of NovaBay Pharmaceuticals worth $697,000 at the end of the most recent reporting period.

NovaBay Pharmaceuticals Company Profile (NYSEAMERICAN:NBY)

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets non-antibiotic and anti-infective products for the eye care market in the United States, China, and internationally. It offers Avenova, a prescription product for cleansing and removing foreign materials, including microorganisms and debris from skin around the eye; NeutroPhase for wound care market; CelleRx for the aesthetic dermatology market; Aganocide compounds patented synthetic molecules for use against bacteria, viruses, and fungi; auriclosene irrigation solution for urology; and intelli-Case, a device for soft and rigid gas permeable contact lenses.

Recommended Story: How to calculate the annual rate of depreciation

Receive News & Ratings for NovaBay Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.